IMA-203 CD8

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameIMA-203 CD8

Drug Alias NameIMA-203 CD8IMA-203CD8IMA-203CD8 GEN2

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityMelanoma antigen preferentially expressed in tumors modulators

TargetsMelanoma antigen preferentially expressed in tumors

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesImmatics Us Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmatics Us Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A